Tivic Health Systems, Inc. (TIVC)
NASDAQ: TIVC · Real-Time Price · USD
0.459
-0.051 (-9.92%)
At close: Feb 21, 2025, 4:00 PM
0.450
-0.009 (-2.05%)
After-hours: Feb 21, 2025, 7:59 PM EST
Tivic Health Systems Revenue
Tivic Health Systems had revenue of $126.00K in the quarter ending September 30, 2024, a decrease of -55.32%. This brings the company's revenue in the last twelve months to $957.00K, down -22.00% year-over-year. In the year 2023, Tivic Health Systems had annual revenue of $1.18M, down -36.09%.
Revenue (ttm)
$957.00K
Revenue Growth
-22.00%
P/S Ratio
1.58
Revenue / Employee
$106,333
Employees
9
Market Cap
4.35M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.18M | -664.00K | -36.09% |
Dec 31, 2022 | 1.84M | 583.00K | 46.38% |
Dec 31, 2021 | 1.26M | 397.00K | 46.16% |
Dec 31, 2020 | 860.00K | 440.00K | 104.76% |
Dec 31, 2019 | 420.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TIVC News
- 10 days ago - Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma - Business Wire
- 2 months ago - CEO Letter to Shareholders Issued by Tivic Health - Business Wire
- 3 months ago - Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 3 months ago - Tivic Health Systems, Inc. (TIVC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device - Business Wire
- 3 months ago - Tivic Health Validates European Patents in Great Britain, Germany, and France - Business Wire
- 3 months ago - Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14 - Business Wire
- 4 months ago - First Subject Enrolled in Tivic Health's Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device - Business Wire